ASMB
NASDAQAssembly Biosciences Inc.
News · 26 weeks43+214%
2025-12-142026-06-07
Mix4190d
- Insider17(41%)
- SEC Filings15(37%)
- Other9(22%)
Latest news
25 items- INSIDERChief Medical Officer Gaggar Anuj was granted 14,000 shares, increasing direct ownership by 49% to 42,688 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Manufacturing Officer White Nicole S was granted 14,000 shares, increasing direct ownership by 41% to 48,145 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Mchutchison John G4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahony Susan4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson-Pratt Lisa4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Houghton Michael4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Consylman Gina4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Altig Anthony E4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERPFO and PAO Bjorkquist Jeanette M was granted 3,500 shares, increasing direct ownership by 32% to 14,589 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Scientific Officer Delaney William E Iv was granted 14,000 shares, increasing direct ownership by 30% to 60,330 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERCEO and President Okazaki Jason A was granted 50,750 shares, increasing direct ownership by 45% to 163,354 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Announces Upcoming Investor Conference PresentationsSOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences: Jefferies 2026 Global Healthcare ConferenceDate: June 3, 2026Time: 4:20 p.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: June 8, 2026Time: 8:40 a.m. ET To register for either webcast, please visit the Events and Presentations section of Assembly Bio's website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible following each
- INSIDERLarge owner Gilead Sciences, Inc. was granted 471,698 shares, increasing direct ownership by 10% to 4,977,089 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Assembly Biosciences Inc.SCHEDULE 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesSOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shares of common stock. In addition, and in lieu of common stock, Assembly Bio sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 415,000 shares of common stock a
- SECSEC Form 424B5 filed by Assembly Biosciences Inc.424B5 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- SECSEC Form 424B5 filed by Assembly Biosciences Inc.424B5 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26.50, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 exercise price per share for each pre-fu
- PRAssembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), broadening the program into cholestatic liver diseases. "We are excited to expand the
- PRAssembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain. "We are pleased to present additional Phase 1a data on ABI-6250 at EASL," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "As the only oral entry inhibitor currently in clinical development for chronic
- PRAssembly Biosciences to Present at the BofA Securities 2026 Global Health Care ConferenceSOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, chief medical officer, will present during the Bank of America Securities 2026 Global Health Care Conference at 4:35 p.m. Pacific Time on May 13, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio's website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations. About Assembly Biosciences Assembly B
- SECSEC Form 10-Q filed by Assembly Biosciences Inc.10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
ASMB FAQ
7 questionsWhat does Assembly Biosciences Inc. do?
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well...Where does ASMB stock trade?
Assembly Biosciences Inc. (ASMB) is listed on NASDAQ.What sector and industry is ASMB in?
Assembly Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Assembly Biosciences Inc. go public?
Assembly Biosciences Inc. (ASMB) completed its IPO in 2010.What are analysts saying about ASMB?
Assembly Biosciences Inc. has had 6 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $3800.00 price target on 2025-09-24.What companies are similar to ASMB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ASMB side-by-side with any of them on Quantisnow.How can I track ASMB on Quantisnow?
Quantisnow aggregates Assembly Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASMB to receive live email and push alerts on every new disclosure.